Citations

Showing 10 of 108081 citations.

Microfibrillar-associated Protein 4 as Potential Marker of Acute Relapse in Inflammatory Demyelinating Diseases of the Central Nervous System: Pathological and Clinical Aspects
Olesen, Mads Nikolaj , Wirenfeldt, Martin , Ruprecht, Klemens , Marignier, Romain , Lillevang, Søren Thue , Pittock, Sean J. , Kim, Ho Jin , Pittock, S J , Samadzadeh, Sara , Möller, Sören , Misu, Tatsuro , Soelberg, Kerstin , Frederiksen, Jette Lautrup , Heegaard, Steffen , Mariotto, Sara , Fujihara, Kazuo , Andersen, Thomas Levin , Flanagan, Eoin P. , Bennett, Jeffrey L. , Paul, Friedemann , Sørensen, Grith Lykke , Weinshenker, Brian G. , Lassmann, Hans , Asgari, Nasrin

Mayo Clinic

No container title available | April 12, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2787239/v1 Get It

Abstract Background and Objectives: Microfibrillar-associated protein 4 (MFAP4) is an extracellular matrix protein not previously described in the central nervous system (CNS). We aimed to determine MFAP4 CNS expression and measure cerebrospinal fluid (CSF) and serum levels. Methods: Tissue was sampled at autopsy from patients with acute multiple sclerosis (MS) (n=3), progressive MS (n=3), neuromyelitis optica spectrum disorder (NMOSD) (n=2), controls (n=9), including 6 healthy controls (HC). MFAP4 levels were measured in 152 patients (49 MS, 62 NMOSD, 22 myelin oligodendrocyte glycoprotein associated disease (MOGAD), and 19 isolated optic neuritis (ION). Results: MFAP4 localized to the meninges and the vascular/perivascular spaces, particularly intense in the optic nerve. At sites of active inflammation, MFAP4 reactivity was reduced in NMOSD and acute MS and to a lesser degree in progressive MS. CSF MFAP4 levels were reduced in patients during acute attacks compared to HC. There was a positive correlation between number of relapses and CSF MFAP4 levels (rho=0.33, p=0.004). CSF MFAP4 levels were lower in 53 samples obtained at presenting attack (mean U/mL: 14.3, MOGAD 9.7 and ION 14.6 relative to HC 17.9. (p=0.013, p=0.000 and p=0.019 respectively). All patients with acute ON relapse (n=68) had reduced CSF MFAP4 relative to HC (mean U/mL: 14.5 vs. 17.9, p=0.006). CSF MFAP4 levels correlated negatively with relapse severity (rho=-0.41, p=0.017). Discussion.: MFAP4 immunoreactivity was observed in CNS and reduced at sites of active inflammation. CSF levels of MFAP4 were reduced following acute relapse and may serve as a marker of disease activity and attack severity.
Corticocerebellar White Matter Integrity Is Related to Naming Outcome in Post-Stroke Aphasia
Keser, Zafer , Stockbridge, Melissa D. , Sebastian, Rajani , Stockbridge, Melissa D , Breining, Bonnie L , Hillis, Argye Elizabeth , Sebastian, Rajani , Keser, Zafer , Meier, Erin L.

Mayo Clinic

Neurobiology of Language | April 12, 2023 | Volume: 4 | Issue: 3 | Pages: 404-419

10.1162/nol_a_00107 | PMID 37588128 Get It

Abstract Studies have shown that the integrity of white matter tracts connecting different regions in the left cerebral hemisphere is important for aphasia recovery after stroke. However, the impact of the underlying structural connection between the cortex and the cerebellum in post-stroke aphasia is poorly understood. We studied the microstructural integrity of the cerebellum and the corticocerebellar connections and their role in picture naming. Fifty-six patients with left cerebral infarcts (sparing the cerebellum) underwent diffusion tensor imaging (DTI) and Boston Naming Test. We compared the fractional anisotropy (FA) and mean diffusivity (MD) values of the right and the left cerebellum (lobular gray and white matter structures) and cerebellocortical connections. Recursive feature elimination and Spearman correlation analyses were performed to evaluate the relationship between naming performance and the corticocerebellar connections. We found that the right, relative to left, cerebellar structures and their connections with the left cerebrum showed lower FA and higher MD values, both reflecting lower microstructural integrity. This trend was not observed in the healthy controls. Higher MD values of the right major cerebellar outflow tract were associated with poorer picture naming performance. Our study provides the first DTI data demonstrating the critical importance of ascending and descending corticocerebellar connections for naming outcomes after stroke.
Automated Image Processing Utilizing Generative Modeling Reveals Novel Insight into Basal Body Duplication and Organization in Tetrahymena
Carmichael, Stephen W., Salisbury, Jeffrey L.

Mayo Clinic

Microscopy Today | April 12, 2023 | Volume: 31 | Issue: 2 | Pages: 8-9

10.1093/mictod/qaad014 Get It

Association of Year of Surgery and Carotid Stenting Outcomes in High-risk Patients, 2015-2021
Stonko, David P. , Bose, Sanuja , Keegan, Alana , Stonko, David P , McDermott, Katherine M. , Morrison, Jonathan J. , Hicks, Caitlin W.

Mayo Clinic

JAMA Surgery | April 12, 2023 | Volume: 158 | Issue: 7 | Pages: 768

10.1001/jamasurg.2022.8384 | PMID 37043232 Get It

This cohort study quantifies the yearly trends and outcomes of transcarotid artery revascularization vs transfemoral carotid artery stenting among high-risk patients from 2015 to 2021.
Paradoxical Psoriasiform Eruptions in Children Receiving Tumor Necrosis Factor α Inhibitors
Eickstaedt, Joshua B. , Lund, Emily , Murphrey, Morgan , Brandling‐Bennett, Heather A. , Maurano, Megan , Holland, Kristen E. , Ibler, Erin, Liang, Marilyn G. , Todd, Patricia , Siegfried, Elaine C. , Igelman, Sean, Tollefson, Megha M. , Paller, Amy S. , Faith, Esteban Fernández , Igelman, Sean, Cordoro, Kelly M.

Mayo Clinic

JAMA Dermatology | April 12, 2023 | Volume: 159 | Issue: 6 | Pages: 637

10.1001/jamadermatol.2023.0549 | PMID 37043214 Get It

ImportanceTumor necrosis factor α (TNF) inhibitor–induced psoriasiform eruption is well recognized in adults, but few reports document this paradoxical effect in children.ObjectiveTo characterize the clinical features and the clinical time course of TNF inhibitor–induced psoriasiform eruptions in children.Design, Setting, and ParticipantsA multicenter retrospective case series of children younger than 18 years seen between January 1, 2000, and December 31, 2016, who developed a new-onset psoriasiform eruption while taking a TNF inhibitor for a nondermatologic disorder. Participating sites were members of the Pediatric Dermatology Research Alliance. Data were entered into a Research Electronic Data Capture database at the Mayo Clinic (ie, the coordinating center).ResultsPsoriasiform eruptions were identified in 103 TNF inhibitor–treated patients (median age, 13.8 years [IQR, 11.7-16.4 years]; 52 female patients [50%]; 57 White patients [55%]), with 67 patients (65%) treated with infliximab, 35 (34%) with adalimumab, and 1 (1%) with certolizumab pegol. Most patients had no personal history (101 [98%]) or family history of psoriasis (60 patients [58%]). Inflammatory bowel disease was the most common indication for treatment with TNF inhibitor (94 patients [91%]). The primary extracutaneous disease was under control in 95 patients (92%) who developed the eruption. Most patients (n = 85 [83%]) developed psoriasiform eruptions at multiple anatomic sites, with scalp involvement being most common (65 patients [63%]). Skin disease developed at a median of 14.5 months (IQR, 9-24 months) after TNF inhibitor initiation. To treat the psoriasiform eruption, topical steroidal and nonsteroidal medication was prescribed for all patients. Systemic therapy was added for 30 patients (29%): methotrexate for 24 patients (23%), oral corticosteroids for 8 patients (8%), and azathioprine for 1 patient (1%). For 26 patients (25%), suboptimal effectiveness with topical medications alone prompted discontinuation of the initial TNF inhibitor and a change to a second-line TNF inhibitor with cutaneous improvement in 23 patients (88%) by a median of 3 months (IQR, 2-4 months). Eight patients (31%) who started a second-line TNF inhibitor developed a subsequent TNF inhibitor–induced psoriasiform eruption at a median of 6 months (IQR, 4-8 months). Persistent skin disease in 18 patients (17%) prompted discontinuation of all TNF inhibitors; 11 patients changed to a non-TNF inhibitor systemic therapy, and 7 discontinued all systemic therapy.Conclusions and RelevanceIn this case series, paradoxical TNF inhibitor–induced psoriasiform eruptions were seen in children treated with TNF inhibitors for any indication, and there appears to be a class effect among the varying TNF inhibitors. The majority of these children were able to continue TNF inhibitor therapy with adequate skin-directed and other adjuvant therapies.
Determinants of physician assessment of chronic rhinosinusitis disease control using EPOS 2020 criteria and the importance of incorporating patient perspectives of disease control
Sedaghat, Ahmad R. , Caradonna, David S., Franzese, Christine B., Gray, Stacey T. , Halderman, Ashleigh A. , Hopkins, Claire , Lee, Jivianne T. , McCoul, Edward D. , O’Brien, Erin K. , Pynnonen, Melissa A., Wise, Sarah K. , Woodworth, Bradford A. , Phillips, Katie M. , Hopkins, Claire , Kuan, Edward C , McCoul, Edward D , Wang, Eric W , Woodworth, Bradford A , Yao, William C , O'Brien, Erin K , Chandra, Rakesh Kumar , Pletcher, Steven D. , Yao, William C.

Mayo Clinic

International Forum of Allergy & Rhinology | April 12, 2023 | Volume: 13 | Issue: 11 | Pages: 2004-2017

10.1002/alr.23168 | PMID 37042828 Get It

AbstractBackgroundWe identify chronic rhinosinusitis (CRS) manifestations associated with how rhinologists assess CRS control, with a focus on patient perspectives (patient‐reported CRS control).MethodsFifteen rhinologists were provided with real‐world data from 200 CRS patients. Participating rhinologists first classified patients’ CRS control as “controlled,” “partly controlled,” and “uncontrolled” using seven CRS manifestations reflecting European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) CRS control criteria (nasal obstruction, drainage, impaired smell, facial pain/pressure, sleep disturbance, use of systemic antibiotics/corticosteroids in past 6 months, and nasal endoscopy findings) and patient‐reported CRS control. They then classified patients’ CRS control without knowledge of patient‐reported CRS control. Interrater reliability and agreement of rhinologist‐assessed CRS control with patient‐reported CRS control and EPOS guidelines were determined.ResultsCRS control classification with and without knowledge of patient‐reported CRS control was highly consistent across rhinologists (κw = 0.758). Rhinologist‐assessed CRS control agreed with patient‐reported CRS control significantly better when rhinologists had knowledge of patient‐reported CRS control (κw = 0.736 vs. κw = 0.554, p < 0.001). Patient‐reported CRS control, nasal obstruction, drainage, and endoscopy findings were most strongly associated with rhinologists’ assessment of CRS control. Rhinologists’ CRS control assessments weakly agreed with EPOS CRS control guidelines with (κw = 0.529) and without (κw = 0.538) patient‐reported CRS control. Rhinologists classified CRS as more controlled than EPOS guidelines in almost 50% of cases.ConclusionsThis study directly demonstrates the importance of patient‐reported CRS control as a dominant influence on rhinologists’ CRS control assessment. Knowledge of patient‐reported CRS control may better align rhinologists’ CRS control assessments and treatment decisions with patients’ perspectives.
Perturbation-Based Training on Compliant Surfaces to Improve Balance in Children With Cerebral Palsy: A Feasibility Study
Phillips, Connor , Phan, Vu , Jo, Kwanghee, Save, Omik , Russell, Joshua, Zeien, Kayla B., Eikenberry, Megan , Kinney, Carolyn L. , Lee, Hyunglae , Kinney, Carolyn , Russell, Joshua B.

Mayo Clinic

IEEE Transactions on Medical Robotics and Bionics | April 12, 2023 | Volume: 5 | Issue: 2 | Pages: 242-252

10.1109/tmrb.2023.3265711 Get It

Translational relevance of SOS1 targeting for KRAS‐mutant colorectal cancer
Alem, Diego , Beato, Francisca , Sarcar, Bhaswati , Tassielli, Alexandra F. , Dai, Ruifan , Hogenson, Tara L. , Park, Margaret A. , Yuan, Yu, Fernández-Zapico, Martín E. , Tan, Aik Choon , Fleming, Jason B. , Tan, Aik Choon , Yang, Xinrui , Jiang, Kun , Cai, Jianfeng , Xie, Hao

Mayo Clinic

Molecular Carcinogenesis | April 12, 2023 | Volume: 62 | Issue: 7 | Pages: 1025-1037

10.1002/mc.23543 | PMID 37042566 Get It

AbstractIt has been challenging to target mutant KRAS (mKRAS) in colorectal cancer (CRC) and other malignancies. Recent efforts have focused on developing inhibitors blocking molecules essential for KRAS activity. In this regard, SOS1 inhibition has arisen as an attractive approach for mKRAS CRC given its essential role as a guanine nucleotide exchange factor for this GTPase. Here, we demonstrated the translational value of SOS1 blockade in mKRAS CRC. We used CRC patient‐derived organoids (PDOs) as preclinical models to evaluate their sensitivity to SOS1 inhibitor BI3406. A combination of in silico analyses and wet lab techniques was utilized to define potential predictive markers for SOS1 sensitivity and potential mechanisms of resistance in CRC. RNA‐seq analysis of CRC PDOs revealed two groups of CRC PDOs with differential sensitivities to SOS1 inhibitor BI3406. The resistant group was enriched in gene sets involving cholesterol homeostasis, epithelial−mesenchymal transition, and TNF‐α/NFκB signaling. Expression analysis identified a significant correlation between SOS1 and SOS2 mRNA levels (Spearman's ρ 0.56, p < 0.001). SOS1/2 protein expression was universally present with heterogeneous patterns in CRC cells but only minimal to none in surrounding nonmalignant cells. Only SOS1 protein expression was associated with worse survival in patients with RAS/RAF mutant CRC (p = 0.04). We also found that SOS1/SOS2 protein expression ratio >1 by immunohistochemistry (p = 0.03) instead of KRAS mutation (p = 1) was a better predictive marker to BI3406 sensitivity of CRC PDOs, concordant with the significant positive correlation between SOS1/SOS2 protein expression ratio and SOS1 dependency. Finally, we showed that GTP‐bound RAS level underwent rebound even in BI3406‐sensitive PDOs with no change of KRAS downstream effector genes, thus suggesting upregulation of guanine nucleotide exchange factor as potential cellular adaptation mechanisms to SOS1 inhibition. Taken together, our results show that high SOS1/SOS2 protein expression ratio predicts sensitivity to SOS1 inhibition and support further clinical development of SOS1‐targeting agents in CRC.
Interrater Reliability of Functional Lumen Imaging Probe Panometry and High-Resolution Manometry for the Assessment of Esophageal Motility Disorders
Chen, Joan W. , Khan, Abraham, Chokshi, Reena V. , Clarke, John O. , Garza, Jose M. , Gupta, Milli , Gyawali, C. Prakash , Jain, Anand , Katz, Philip O. , Konda, Vani J. , Lazarescu, Adriana , Lynch, Kristle L. , Schnoll‐Sussman, Felice , Vela, Marcelo F. , Schauer, Jacob M. , Pandolfino, John E. , Carlson, Dustin A. , Clarke, J , Gyawali, C P , Chen, Joan , Khan, Abraham, Fass, Ronnie , Spechler, Stuart Jon , Yadlapati, Rena , Kahrilas, Peter J.

Mayo Clinic

American Journal of Gastroenterology | April 12, 2023 | Volume: 118 | Issue: 8 | Pages: 1334-1343

10.14309/ajg.0000000000002285 | PMID 37042784 Get It

INTRODUCTION: High-resolution manometry (HRM) and functional lumen imaging probe (FLIP) are primary and/or complementary diagnostic tools for the evaluation of esophageal motility. We aimed to assess the interrater agreement and accuracy of HRM and FLIP interpretations. METHODS: Esophageal motility specialists from multiple institutions completed the interpretation of 40 consecutive HRM and 40 FLIP studies. Interrater agreement was assessed using intraclass correlation coefficient (ICC) for continuous variables and Fleiss' κ statistics for nominal variables. Accuracies of rater interpretation were assessed using the consensus of 3 experienced raters as the reference standard. RESULTS: Fifteen raters completed the HRM and FLIP studies. An excellent interrater agreement was seen in supine median integral relaxation pressure (ICC 0.96, 95% confidence interval 0.95–0.98), and a good agreement was seen with the assessment of esophagogastric junction (EGJ) outflow, peristalsis, and assignment of a Chicago Classification version 4.0 diagnosis using HRM (κ = 0.71, 0.75, and 0.70, respectively). An excellent interrater agreement for EGJ distensibility index and maximum diameter (0.91 [0.90–0.94], 0.92 [0.89–0.95]) was seen, and a moderate-to-good agreement was seen in the assignment of EGJ opening classification, contractile response pattern, and motility classification (κ = 0.68, 0.56, and 0.59, respectively) on FLIP. Rater accuracy for Chicago Classification version 4.0 diagnosis on HRM was 82% (95% confidence interval 78%–84%) and for motility diagnosis on FLIP Panometry was 78% (95% confidence interval 72%–81%). DISCUSSION: Our study demonstrates high levels of interrater agreement and accuracy in the interpretation of HRM and FLIP metrics and moderate-to-high levels for motility classification in FLIP, supporting the use of these approaches for primary or complementary evaluation of esophageal motility disorders.
Affecting Computing in Multimodal Mobility
Dangi, Priyal, Garg, Muskan

Mayo Clinic

Advances in Wireless Technologies and Telecommunication | April 12, 2023 | Volume: No volume available | Issue: No issue available | Pages: 351-370

10.4018/978-1-6684-8582-8.ch019 Get It

Computational models that simulate human emotions have witnessed a substantial development in recent years for widening the spectrum of applications. Emotional computation is becoming crucial in human-to-computer interactions with exponential growth of artificial intelligence. Normally referred to as emotion recognition, it is widely believed that the prospective detection of a person's emotional state of mind should be computed from their facial expressions. Face-movement combinations may express many different emotion types, for instance, hate, anger, panic, joy, grief, surprise, shock, to name a few. The goal and emphasis of this manuscript is the deployment of different algorithms and computation models for emotions. Considerable advancements in this domain of emotion recognition can be made through AI model development that discusses the challenges of the system and Facial Action Coding as an integral part of the models.